Pfizer Inc. (NYSE:PFE) Stock Holdings Reduced by Fjarde AP Fonden Fourth Swedish National Pension Fund

Key Points

• The Fjarde AP Fonden Fourth Swedish National Pension Fund sold 549,500 shares of Pfizer Inc., reducing its stake by 40.9%, leaving it with 794,271 shares valued at approximately $20.1 million.
• Pfizer reported earnings per share (EPS) of $0.78 for the last quarter, significantly outperforming the consensus estimate of $0.58 and showing a revenue increase of 10.3% year-over-year.
• Pfizer announced a quarterly dividend of $0.43, translating to an annual yield of 6.8%, with a payout ratio of 91.49%.

Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 40.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 794,271 shares of the biopharmaceutical company's stock after selling 549,500 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Pfizer were worth $20,127,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Bessemer Group Inc. increased its position in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK increased its position in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Pfizer during the 1st quarter valued at $8,283,000. Alta Advisers Ltd increased its position in shares of Pfizer by 69.6% during the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after purchasing an additional 13,100 shares during the period. Finally, WCM Investment Management LLC increased its position in shares of Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after purchasing an additional 10,051 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.2%

Shares of Pfizer stock traded up $0.05 during midday trading on Friday, hitting $25.16. The company's stock had a trading volume of 31,819,451 shares, compared to its average volume of 45,227,284. The firm has a market capitalization of $143.05 billion, a P/E ratio of 13.38, a PEG ratio of 0.89 and a beta of 0.52. The stock has a 50-day simple moving average of $24.60 and a 200-day simple moving average of $24.45. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.